19 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이민형-
dc.date.accessioned2019-12-03T00:34:36Z-
dc.date.available2019-12-03T00:34:36Z-
dc.date.issued2017-12-
dc.identifier.citationJOURNAL OF CONTROLLED RELEASE, v. 268, page. 305-313en_US
dc.identifier.issn0168-3659-
dc.identifier.issn1873-4995-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0168365917308179?via%3Dihub-
dc.identifier.urihttp://repository.hanyang.ac.kr/handle/20.500.11754/116576-
dc.description.abstractThe number of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly basis. Current anti-diabetic medications often result in adverse weight gain and hypoglycemic episodes. Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which are expensive and require daily injections that may result immune activation. This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of bile acids. Oral administration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model. This novel oral GLP1 delivery system is an attractive alternative to treat late-stage T2DM conditions that require repeated insulin injection and can potentially minimize the occurrence of hypoglycemic anomalies.en_US
dc.description.sponsorshipThis study was supported by a grant from the National Leading Research Laboratory (NRF-2015R1A2A1A05001832) through the National Research Foundation of Korea (NRF) funded by the Korean Government. This study was also supported by a grant from the Basic Science Research Program (2015R1D1A1A09060567, NRF-2014R1A2A2A03004802) through the National Research Foundation of Korea (NRF) funded by Korea Government. This study was also supported by a grant from the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C2099).en_US
dc.language.isoen_USen_US
dc.publisherELSEVIER SCIENCE BVen_US
dc.subjectDiabetesen_US
dc.subjectPeptide nanoparticleen_US
dc.subjectOral deliveryen_US
dc.subjectHypoglycemiaen_US
dc.subjectAnti-obesityen_US
dc.titleOral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetesen_US
dc.typeArticleen_US
dc.relation.volume268-
dc.identifier.doi10.1016/j.jconrel.2017.08.035-
dc.relation.page305-313-
dc.relation.journalJOURNAL OF CONTROLLED RELEASE-
dc.contributor.googleauthorNurunnabi, Md-
dc.contributor.googleauthorLee, Seung-Ah-
dc.contributor.googleauthorRevuri, Vishnu-
dc.contributor.googleauthorHwang, Yong Hwa-
dc.contributor.googleauthorKang, Sung Hun-
dc.contributor.googleauthorLee, Minhyung-
dc.contributor.googleauthorCho, Sungpil-
dc.contributor.googleauthorCho, Kwang Jae-
dc.contributor.googleauthorByun, Youngro-
dc.contributor.googleauthorBae, You Han-
dc.relation.code2017003061-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDEPARTMENT OF BIOENGINEERING-
dc.identifier.pidminhyung-
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE